Sweden
Buzzard Pharmaceuticals is a biopharmaceutical development company focused on developing Isunakinra, an IL-1 inhibitor, for the treatment of cancer. Isunakinra (EBI-005) is a potent recombinant protein that binds to the IL1R1 with high potency. The company's approach targets the inhibition of IL-1, which mediates the recruitment of immunesuppressive myeloid cells (PMN-MDSCs, neutrophils, and T2 macrophages) to the tumor, inhibiting CD8 T cells from entering the tumor and killing tumor cells. In addition, IL-1 also stimulates angiogenesis and tumor spread.
Founded in 2016, the company's mission is to leverage Isunakinra as an Immuno-Oncology agent. Introducing an innovative solution in the treatment of cancer, Buzzard Pharmaceuticals aims to address critical aspects of tumor growth and immune response.
